Evolent Health, Inc. (EVH) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on December 1, 2025, covering events occurring on December 1 and December 2, 2025. The filing primarily addresses changes to the Board of Directors and reaffirms financial guidance for the fourth quarter of 2025.
Key Financial Metrics and Guidance
The filing does not report historical revenue, profit, cash flow, or debt figures for the period. Instead, it provides forward-looking guidance for the fourth quarter of 2025:
- Q4 2025 Revenue Guidance: Approximately $462.0 million to $472.0 million.
- Q4 2025 Adjusted EBITDA Guidance: Approximately $30.0 million to $40.0 million.
The Company states it cannot meaningfully reconcile Adjusted EBITDA guidance to net income due to the inability to forecast significant reconciling items without unreasonable effort. These items may include stock-based compensation, transaction-related costs, and changes in fair value of contingent consideration.
Material Changes and Corporate Governance
Significant changes to the Board of Directors were reported:
- Departure: Ms. Cheryl Scott retired from the Board on December 1, 2025. The Board accelerated the vesting of 21,979 restricted stock units (RSUs) previously scheduled to vest in 2026. The retirement was not due to any disagreement with the Company.
- Appointment: Ms. Jill Smith was appointed to the Board on December 2, 2025, with a term expiring at the 2026 Annual Meeting. Ms. Smith brings over 25 years of business leadership experience, including prior CEO roles at Allied Minds plc and DigitalGlobe Inc.
Outlook, Risks, and Management Commentary
Senior management is scheduled to meet with investors and analysts between December 2 and December 16, 2025. The guidance reaffirmed in this filing is consistent with the press release issued on November 6, 2025. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks and uncertainties discussed in the Company's 2024 Form 10-K and 2025 Form 10-Q.
Key Facts for Investor Verification
- Verify the exact vesting terms and tax implications of the accelerated RSUs granted to the retiring director.
- Confirm the specific composition of the "significant reconciling items" excluded from the Adjusted EBITDA guidance in future earnings reports.
- Monitor upcoming investor meetings (Dec 2–16, 2025) for any updates to the Q4 2025 revenue and Adjusted EBITDA ranges.
- Review Ms. Jill Smith's full background and potential conflicts of interest given her prior roles in healthcare and technology sectors.